OXFORD, UK, October 1st, 2014
PharmaVentures is pleased to announce that it has acted as advisor on deal terms to Plethora Solutions Holdings on their recently signed Licensing Agreement with Recordati to commercialise PSD502™, a novel treatment for premature ejaculation.
Under the terms of the agreement Plethora are expected to receive upfront and milestone payments of up to €46 million plus royalties.
Stephen Waterman, Vice President, who led the PharmaVentures team on the deal commented: “We are delighted to have worked with Plethora on the deal terms of this important licensing agreement”.
Fintan Walton, Chief Executive, PharmaVentures, Ltd added: “We would like to congratulate Plethora on their licensing agreement with Recordati”.
– ends –